BioTime Inc. (BTX)

0.92
AMEX : Health Technology
Prev Close 0.99
Day Low/High 0.90 / 0.97
52 Wk Low/High 0.66 / 2.61
Avg Volume 459.10K
Exchange AMEX
Shares Outstanding 149.64M
Market Cap 148.15M
EPS -0.40
P/E Ratio 4.60
Div & Yield N.A. (N.A)
BioTime’s Subsidiary OncoCyte Corporation Provides An Update On The Development Of The Novel Pan-Cancer Diagnostic Product PanC-DxTM

BioTime’s Subsidiary OncoCyte Corporation Provides An Update On The Development Of The Novel Pan-Cancer Diagnostic Product PanC-DxTM

BioTime, Inc. (NYSE MKT: BTX) and BioTime’s subsidiary OncoCyte Corporation provided an update on the progress of development of PanC-Dx TM, a novel blood-based diagnostic test utilizing molecular markers ...

BioTime CEO Dr. Michael West To Present At Scale-Up And Manufacturing Of Cell-Based Therapies II Conference

BioTime CEO Dr. Michael West To Present At Scale-Up And Manufacturing Of Cell-Based Therapies II Conference

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D.

BioTime Submits Protocol For Initiation Of Human Clinical Trials Of Renevia™ In Europe

BioTime Submits Protocol For Initiation Of Human Clinical Trials Of Renevia™ In Europe

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced it has submitted a Clinical Investigation Protocol (CIP) to European ...

LifeMap Sciences, A Subsidiary Of BioTime, Inc., Announces The Release Of MalaCards Version 1.02

LifeMap Sciences, A Subsidiary Of BioTime, Inc., Announces The Release Of MalaCards Version 1.02

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc.

BioTime Signs Definitive Agreement With Geron Regarding Stem Cell Assets

BioTime Signs Definitive Agreement With Geron Regarding Stem Cell Assets

BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a definitive Asset Contribution Agreement with Geron ...

BioTime Announces The Appointment Of Jeffrey Janus As Vice President

BioTime Announces The Appointment Of Jeffrey Janus As Vice President

BioTime, Inc. (NYSE MKT: BTX) today announced the appointment of Jeffrey Janus as its Vice President of Sales and Marketing.

BioTime Reports Isolation Of Seven Diverse Cartilage And Bone Cell Types From Human Embryonic Stem Cells

BioTime Reports Isolation Of Seven Diverse Cartilage And Bone Cell Types From Human Embryonic Stem Cells

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, and its subsidiaries OrthoCyte Corporation and LifeMap Sciences reported today a means of...

BioTime CEO Dr. Michael West Presents Product Development Update At World Stem Cell Summit 2012

BioTime CEO Dr. Michael West Presents Product Development Update At World Stem Cell Summit 2012

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D.

BioTime CEO Dr. Michael West To Present At World Stem Cell Summit 2012

BioTime CEO Dr. Michael West To Present At World Stem Cell Summit 2012

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D.

BioTime Announces Passing Of Director Abraham E. Cohen

BioTime Announces Passing Of Director Abraham E. Cohen

BioTime, Inc. (NYSE MKT: BTX) announced with sadness that Abraham (Barry) E.

LifeMap Sciences, A Subsidiary Of BioTime, Signs Definitive Distribution Agreement With ProSpec-Tany TechnoGene

LifeMap Sciences, A Subsidiary Of BioTime, Signs Definitive Distribution Agreement With ProSpec-Tany TechnoGene

LifeMap Sciences, Inc. a subsidiary of BioTime, Inc.

LifeMap Sciences, A Subsidiary Of BioTime, Announces Release Of GeneCards® Version 3.09

LifeMap Sciences, A Subsidiary Of BioTime, Announces Release Of GeneCards® Version 3.09

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc.

BioTime And BioTime Acquisition Corporation Announce Combined $10 Million Financing

BioTime And BioTime Acquisition Corporation Announce Combined $10 Million Financing

BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a non-binding letter of intent for a $10 million investment ...

BioTime Announces Non-Binding Letter Of Intent With Geron Regarding Stem Cell Assets

BioTime Announces Non-Binding Letter Of Intent With Geron Regarding Stem Cell Assets

BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a non-binding letter of intent (LOI) with Geron Corporation.

BioTime And Subsidiary LifeMap Sciences Announce The Launch Of LifeMap BioReagents™ Portal

BioTime And Subsidiary LifeMap Sciences Announce The Launch Of LifeMap BioReagents™ Portal

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences have announced the launch of LifeMap BioReagents™ ( http://bioreagents.

BioTime Announces Third Quarter 2012 Financial Results And Recent Corporate Accomplishments

BioTime Announces Third Quarter 2012 Financial Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and year-to-date period ended ...

BioTime And Subsidiary Cell Cure Neurosciences Ltd. Announce Financing

BioTime And Subsidiary Cell Cure Neurosciences Ltd. Announce Financing

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd.

BioTime Subsidiary OrthoCyte Corporation Announces The Appointment Of Francois Binette As Vice President

BioTime Subsidiary OrthoCyte Corporation Announces The Appointment Of Francois Binette As Vice President

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OrthoCyte Corporation today announced the appointment of Francois Binette, PhD, as OrthoCyte’s Vice President of Research and Business Development.

BioTime’s Subsidiary LifeMap Sciences, Inc. Announces The Launch Of MalaCards - A Database Of Human Diseases

BioTime’s Subsidiary LifeMap Sciences, Inc. Announces The Launch Of MalaCards - A Database Of Human Diseases

BioTime, Inc. (NYSE MKT: BTX) and LifeMap Sciences, Inc.

LifeMap Sciences, Inc. Announces Addition To Board Of Directors And Provides Update On Product Portfolio Development

LifeMap Sciences, Inc. Announces Addition To Board Of Directors And Provides Update On Product Portfolio Development

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary, LifeMap Sciences, Inc.

BioTime, Inc. Issues Open Letter To Shareholders Of Geron Corporation

BioTime, Inc. Issues Open Letter To Shareholders Of Geron Corporation

BioTime, Inc. (NYSE MKT: BTX) today issued the following letter to the shareholders of Geron Corporation (Nasdaq: GERN) regarding Geron’s stem cell assets: October 18, 2012 AN OPEN...

BioTime Forms BioTime Acquisition Corporation

BioTime Forms BioTime Acquisition Corporation

BioTime, Inc. (NYSE MKT: BTX), an Alameda-based company engaged in research and development of innovative new products in the field of regenerative medicine utilizing stem cells and related technology, announced today...

BioTime CEO Michael D. West To Present At Stem Cells USA & Regenerative Medicine Congress 2012

BioTime CEO Michael D. West To Present At Stem Cells USA & Regenerative Medicine Congress 2012

BioTime, Inc. (NYSE MKT: BTX) announced that Chief Executive Officer Michael D.

BioTime Obtains Expanded License To HyStem® Technology

BioTime Obtains Expanded License To HyStem® Technology

BioTime, Inc. (NYSE MKT: BTX) announced that the company has amended its license from the University of Utah to expand the field of use for which BioTime is licensed to produce and market products covered by the core ...

BioTime And OncoCyte Corporation Publish Data On The Gene COL10A1 As A Marker And Potential Diagnostic For A Wide Array Of Human Cancers

BioTime And OncoCyte Corporation Publish Data On The Gene COL10A1 As A Marker And Potential Diagnostic For A Wide Array Of Human Cancers

BioTime, Inc. (NYSE MKT: BTX) and BioTime’s subsidiary OncoCyte Corporation today announced the publication of a scientific report on the gene COL10A1 and its potential as a marker for numerous types of human...

BioTime Announces Second Quarter 2012 Financial Results And Recent Corporate Accomplishments

BioTime Announces Second Quarter 2012 Financial Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the second quarter ended June 30, 2012 and ...

BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.33 Million Grant From Israel’s Office Of The Chief Scientist

BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.33 Million Grant From Israel’s Office Of The Chief Scientist

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd.